Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-MCBS Online Tutorials

ESMO-MCBS-1000x250-Online-Tutorials

These ESMO-MCBS video tutorials below provide an overview of the scale and scoring methodology with detailed examples

The ESMO-MCBS is a validated and reproducible tool based on a rational, structured and consistent approach to the interpretation of published clinical trial data that can be used to determine an agent's relative grading in relation to its anticipated clinical benefit in a specific setting.

To find out more, please watch the introduction video below:

ESMO-MCBS-Online-Tutorials-Evaluation-Form-1

Form 1

Evaluation form 1 is used if the treatment is a new adjuvant or neoadjuvant therapy or if it's a new, potentially curative treatment

ESMO-MCBS-Online-Tutorials-Evaluation-Form-2a

Form 2a

Evaluation form 2a is used for agents that are unlikely to be curative and where the clinical trial that led to its licensed indication either: 

  • had a primary endpoint of overall survival, or
  • had a primary endpoint of progression-free survival and a secondary endpoint of OS with mature data showing a significant OS benefit versus the control arm of the trial
ESMO-MCBS-Online-Tutorials-Evaluation-Form-2b

Form 2b

Evaluation form 2b is used for agents that are unlikely to be curative and where the clinical trial that led to its licensed indication had a primary endpoint of progression free survival

ESMO-MCBS-Online-Tutorials-Evaluation-Form-2c

Form 2c

Evaluation form 2c is used for agents that are unlikely to be curative and where the clinical trial that led to its licensed indication had a primary endpoint of quality of life or response rate, or if it was a non-inferiority study

ESMO-MCBS-Online-Tutorials-Evaluation-Form-3

Form 3

Evaluation form 3 is used for single-arm studies in orphan diseases or those with a high unmet need, where the clinical trial that led to its licensed indication had a primary endpoint of progression-free survival or overall response rate. Overall response rate includes all patients that had either a complete or partial response to treatment

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.